Disparate effects of single endothelin-A and-B receptor blocker therapy on the progression of renal injury in advanced renovascular disease

Kidney International

Volumn 85, Issue 4, 2014, Pages 833-844

  Chade, Alejandro R ^a   Stewart, Nicholas J ^a   Peavy, Patrick R ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelin; Hemodynamics; Imaging; Kidney; Microcirculation

Indexed keywords

4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; ATRASENTAN; CREATININE; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; PLACEBO; BIOLOGICAL MARKER; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIAL NITRIC OXIDE SYNTHASE; SUPEROXIDE DISMUTASE;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; EXPERIMENTAL PIG; GLOMERULUS FILTRATION RATE; IN VIVO STUDY; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY INJURY; MICROVASCULAR DENSITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEPHRITIS; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENAL SYSTEM PARAMETERS; RENOVASCULAR DISEASE; ANIMAL; BLOOD; DRUG EFFECTS; HYPERTENSION, RENOVASCULAR; KIDNEY; KIDNEY CIRCULATION; METABOLISM; MICROVASCULATURE; PIG; RENAL ARTERY OBSTRUCTION; VASCULARIZATION; BODY WEIGHT; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; JUVENILE ANIMAL; KIDNEY ARTERY STENOSIS; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY STRUCTURE; MEAN ARTERIAL PRESSURE; PROTEIN EXPRESSION; SWINE;

ANIMALS; BIOLOGICAL MARKERS; ENDOTHELIN A RECEPTOR ANTAGONISTS; ENDOTHELIN B RECEPTOR ANTAGONISTS; ENDOTHELIN-1; HYPERTENSION, RENOVASCULAR; KIDNEY; MICROVESSELS; MULTIDETECTOR COMPUTED TOMOGRAPHY; RENAL ARTERY OBSTRUCTION; RENAL CIRCULATION; SWINE;

EID: 84897954458     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.477     Document Type: Article

References (66)

1. Hansen KJ, Edwards MS, Craven TE et al. Prevalence of renovascular disease in the elderly: A population-based study. J Vasc Surg 2002; 36: 443-451.
2. Dworkin LD. Controversial treatment of atherosclerotic renal vascular disease: The cardiovascular outcomes in renal atherosclerotic lesions trial. Hypertension 2006; 48: 350-356.
3. Dhaun N, Goddard J, Kohan DE et al. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension 2008; 52: 452-459.
4. Chade AR, Rodriguez-Porcel M, Grande JP et al. Distinct renal injury in early atherosclerosis and renovascular disease. Circulation 2002; 106: 1165-1171.
5. Chade AR, Rodriguez-Porcel M, Grande JP et al. Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol 2003; 23: 1295-1301.
6. Lerman LO, Chade AR, Sica V et al. Animal models of hypertension: An overview. J Lab Clin Med 2005; 146: 160-173.
7. Kelsen S, Hall JE, Chade AR. Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease. Am J Physiol Renal Physiol 2011; 301: F218-F225.
8. Iliescu R, Fernandez SR, Kelsen S et al. Role of renal microcirculation in experimental renovascular disease. Nephrol Dial Transplant 2010; 25: 1079-1087.
9. Pipinos II, Nypaver TJ, Moshin SK et al. Response to angiotensin inhibition in rats with sustained renovascular hypertension correlates with response to removing renal artery stenosis. J Vasc Surg 1998; 28: 167-177.
10. Robertson JI, Morton JJ, Tillman DM et al. The pathophysiology of renovascular hypertension. J Hypertens Suppl 1986; 4: S95-S103.
11. Chade AR, Krier JD, Galili O et al. Role of renal cortical neovascularization in experimental hypercholesterolemia. Hypertension 2007; 50: 729-736.
12. Chade AR, Best PJ, Rodriguez-Porcel M et al. Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. Kidney Int 2003; 64: 962-969.
13. Chade AR, Krier JD, Textor SC et al. Endothelin-A receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. J Am Soc Nephrol 2006; 17: 3394-3403.
14. Zager RA, Johnson AC, Andress D et al. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury. Kidney Int 2013; 84: 703-712.
15. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)-summary of recommendations. J Vasc Interv Radiol 2006; 17: 1383-1397.
16. Chrysochou C, Kalra PA. Atherosclerotic renovascular disease and the heart. J Ren Care 2010; 36(Suppl 1): 146-153.
17. Green D, Kalra PA. The heart in atherosclerotic renovascular disease. Front Biosci (Elite Ed) 2012; 4: 856-864.
18. Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007; 47: 731-759.
19. Tharaux PL, Hagege I, Placier S et al. Urinary endothelin-1 as a marker of renal damage in sickle cell disease. Nephrol Dial Transplant 2005; 20: 2408-2413.
20. Arfian N, Emoto N, Vignon-Zellweger N et al. ET-1 deletion from endothelial cells protects the kidney during the extension phase of ischemia/reperfusion injury. Biochem Biophys Res Commun 2012; 425: 443-449.
21. Forbes JM, Hewitson TD, Becker GJ et al. Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-Term kidney function. Kidney Int 2001; 59: 1333-1341.
22. Rautureau Y, Schiffrin EL. Endothelin in hypertension: An update. Curr Opin Nephrol Hhypertens 2012; 21: 128-136.
23. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995; 92: 357-363.
24. Barton M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 2008; 4: 490-501.
25. Barton M. Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. Biochim Biophys Acta 2010; 1802: 1203-1213.
26. Dhaun N, MacIntyre IM, Kerr D et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011; 57: 772-779.
27. Dhaun N, Macintyre IM, Melville V et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension 2009; 54: 113-119.
28. Ortmann J, Amann K, Brandes RP et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004; 44: 974-981.
29. Chade AR, Zhu X, Mushin OP et al. Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J 2006; 20: 1706-1708.
30. Chade AR, Rodriguez-Porcel M, Herrmann J et al. Beneficial effects of antioxidant vitamins on the stenotic kidney. Hypertension 2003; 42: 605-612.
31. Chade AR, Rodriguez-Porcel M, Herrmann J et al. Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol 2004; 15: 958-966.
32. Romero JC, Reckelhoff JF. State-of-The-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34: 943-949.
33. Fukai T. Endothelial GTPCH in eNOS uncoupling and atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 2007; 27: 1493-1495.
34. Li H, Forstermann U. Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Curr Opin Pharmacol 2013; 13: 161-167.
35. Lee S, Chen TT, Barber CL et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130: 691-703.
36. Thanigaimani S, Kichenadasse G, Mangoni AA. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: Lessons from recent trials with anti-VEGF drugs. Curr Vasc Pharmacol 2011; 9: 358-380.
37. Gerritsen ME. HGF and VEGF: A dynamic duo. Circ Res 2005; 96: 272-273.
38. Min JK, Lee YM, Kim JH et al. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res 2005; 96: 300-307.
39. Sulpice E, Ding S, Muscatelli-Groux B et al. Cross-Talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol Cell 2009; 101: 525-539.
40. Egom EE, Mohamed TM, Mamas MA et al. Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. Am J Physiol Heart Circ Physiol 2011; 301: H1487-H1495.
41. Tanimoto T, Jin ZG, Berk BC. Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J Biol Chem 2002; 277: 42997-43001.
42. Zheng H, Dai T, Zhou B et al. SDF-1alpha/CXCR4 decreases endothelial progenitor cells apoptosis under serum deprivation by PI3K/Akt/eNOS pathway. Atherosclerosis 2008; 201: 36-42.
43. Chen YH, Wu HL, Chen CK et al. Angiostatin antagonizes the action of VEGF-A in human endothelial cells via two distinct pathways. Biochem Biophys Res Commun 2003; 310: 804-810.
44. Eriksson K, Magnusson P, Dixelius J et al. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 2003; 536: 19-24.
45. Kitamura H, Shimizu A, Masuda Y et al. Apoptosis in glomerular endothelial cells during the development of glomerulosclerosis in the remnant-kidney model. Exp Nephrol 1998; 6: 328-336.
46. Kelsen S, He X, Chade AR. Early superoxide scavenging accelerates renal microvascular rarefaction and damage in the stenotic kidney. Am J Physiol Renal Physiol 2012; 303: F576-F583.
47. Wu Y, Wang D, Wang X et al. Caspase 3 is activated through caspase 8 instead of caspase 9 during H2O2-induced apoptosis in HeLa cells. Cell Physiol Biochem 2011; 27: 539-546.
48. Kaltschmidt B, Kaltschmidt C, Hofmann TG et al. The pro-or antiapoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. Eur J Biochem 2000; 267: 3828-3835.
49. Essers J, Theil AF, Baldeyron C et al. Nuclear dynamics of PCNA in DNA replication and repair. Mol Cell Biol 2005; 25: 9350-9359.
50. Foster RR, Saleem MA, Mathieson PW et al. Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol 2005; 288: F48-F57.
51. Yo Y, Morishita R, Nakamura S et al. Potential role of hepatocyte growth factor in the maintenance of renal structure: Anti-Apoptotic action of HGF on epithelial cells. Kidney Int 1998; 54: 1128-1138.
52. Deuse T, Peter C, Fedak PW et al. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation 2009; 120: S247-S254.
53. Xue F, Isaka Y, Takahara T et al. HGF-MSP chimera protects kidneys from ischemia-reperfusion injury. Biochem Biophys Res Commun 2007; 363: 451-456.
54. Wen X, Li Y, Hu K et al. Hepatocyte growth factor receptor signaling mediates the anti-fibrotic action of 9-cis-retinoic acid in glomerular mesangial cells. Am J Pathol 2005; 167: 947-957.
55. Ohno-Matsui K, Uetama T, Yoshida T et al. Reduced retinal angiogenesis in MMP-2-deficient mice. Invest Ophthalmol Vis Sci 2003; 44: 5370-5375.
56. Rojiani MV, Alidina J, Esposito N et al. Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp Pathol 2010; 3: 775-781.
57. Zheng H, Takahashi H, Murai Y et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res 2006; 26: 3579-3583.
58. Ozaki S, Ohwaki K, Ihara M et al. Coexpression studies with endothelin receptor subtypes indicate the existence of intracellular cross-Talk between ET(A) and ET(B) receptors. J Biochem 1997; 121: 440-447.
59. Simonson MS, Herman WH. Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signaling by endothelin-1. Cross-Talk between G protein-coupled receptors and pp60c-src. J Biol Chem 1993; 268: 9347-9357.
60. Lerman LO, Schwartz RS, Grande JP et al. Noninvasive evaluation of a novel swine model of renal artery stenosis. J Am Soc Nephrol 1999; 10: 1455-1465.
61. Chade AR, Kelsen S. Reversal of renal dysfunction by targeted administration of VEGF into the stenotic kidney: A novel potential therapeutic approach. Am J Physiol Renal Physiol 2012; 302: F1342-F1350.
62. Stewart N, Chade AR. Renoprotective effects of hepatocyte growth factor in the stenotic kidney. Am J Physiol Renal Physiol 2013; 304: F625-F633.
63. Daghini E, Primak AN, Chade AR et al. Assessment of renal hemodynamics and function in pigs with 64-section multidetector CT: Comparison with electron-beam CT. Radiology 2007; 243: 405-412.
64. Krier JD, Ritman EL, Bajzer Z et al. Noninvasive measurement of concurrent single-kidney perfusion, glomerular filtration, and tubular function. Am J Physiol Renal Physiol 2001; 281: F630-F638.
65. Zhu XY, Chade AR, Rodriguez-Porcel M et al. Cortical microvascular remodeling in the stenotic kidney: Role of increased oxidative stress. Arterioscler Thromb Vasc Biol 2004; 24: 1854-1859.
66. Yang YM, Huang A, Kaley G et al. eNOS uncoupling and endothelial dysfunction in aged vessels. Am J Physiol Heart Circ Physiol 2009; 297: H1829-H1836.